Therapeutic normothermia system

with selective brain cooling

TEQCool develops a temperature control therapy for achieving and maintaining normothermia in the patient’s brain. The primary objective of the treatment is to prevent and manage neurogenic fever in brain-injured patients.

Temperature control is an active treatment to achieve and maintain a specific patient temperature for a certain period of time, in order to improve health outcomes.

TEQCool’s intended therapy is dedicated to achieving and maintaining normothermia in the patient’s brain. The primary objective of the treatment is to prevent and manage neurogenic fever in brain-injured patients. The system will support healthcare professionals to achieve stable normothermia by continuous brain temperature monitoring.

TEQCool AB is a medical technology company based in Lund, Sweden. TEQCool develops a unique, patented solution for selectively cooling the brain of patients with brain-injury suffering from neurogenic fever.